← Leaderboards
David A Williams
Indiana Univ-Purdue Univ At Indianapolis
$57,290,422
Attributed
$74,763,530
Total exposure
42
Grants
35
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$82,593,088 · 45
By mechanism
R01$22,930,258 · 9
U01$21,792,408 · 11
T32$13,071,821 · 1
R24$8,774,776 · 2
RC4$3,876,697 · 1
P01$3,660,032 · 3
Top collaborators
- Mark D Fleming8 shared
- Michael A Pulsipher7 shared
- Benjamin Levine Ebert6 shared
- Kyriacos Markianos6 shared
- Janis L Abkowitz5 shared
- Mary-Claire King5 shared
- Donald B Kohn5 shared
- Akiko Shimamura5 shared
Others in their field
Top investigators on “Hematopoietic Stem Cells”
- Mary M Horowitz · Medical College Of Wisconsin$222,127,419
- Hans-Peter Kiem · Fred Hutchinson Cancer Center$80,540,126
- David T Scadden · Massachusetts General Hospital$40,987,034
- Irving Lerner Weissman · Stanford University$36,281,548
- Bruce R. Blazar · University Of Minnesota$33,175,355
- Marcel R M Van Den Brink · Sloan-Kettering Institute For Cancer Res$31,152,075
Research focus
Hematopoietic Stem CellsCellsHematopoiesisGenesBaseMolecularIn VivoGeneticBlood CellsPhenotypeFutureBiologicalHematopoieticGene TherapySamplingPathway InteractionsFundingIn VitroCell PhysiologyFamilyEngraftmentIncidenceStem CellsMutant
Grant awards (146)
Gene therapy for SCID-X1 with low dose busulfan and a SIN-lentiviral vector$1,305,361
U01 · FY2025 · AI · contact PI
Pathophysiology of Human Blood Cells$1,044,957
T32 · FY2025 · HL · contact PI
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia$704,815
UH3 · FY2025 · HL · contact PI
The role of Septin6 Group in Murine and Human Hematopoiesis$354,000
R01 · FY2025 · DK · contact PI
Pathophysiology of Human Blood Cells$861,806
T32 · FY2024 · HL · contact PI
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia$692,607
UH3 · FY2024 · HL · contact PI
The role of Septin6 Group in Murine and Human Hematopoiesis$339,840
R01 · FY2024 · DK · contact PI
Gene Therapy for SCID-X1 with Low Dose Busulfan and a SIN-lentiviral Vector$1,285,631
U01 · FY2023 · AI · contact PI
Pathophysiology of Human Blood Cells$994,372
T32 · FY2023 · HL · contact PI
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia$704,843
UH3 · FY2023 · HL · contact PI
The role of Septin6 Group in Murine and Human Hematopoiesis$354,000
R01 · FY2023 · DK · contact PI
Pathophysiology of Human Blood Cells$708,572
T32 · FY2022 · HL · contact PI
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia$692,343
UG3 · FY2022 · HL · contact PI
Hematopoietic stem cell gene therapy for infantile neuronal ceroid lipofuscinosis$358,913
R01 · FY2022 · HD · contact PI
Gene therapy for SCID-X1 with low dose busulfan and a SIN-lentiviral vector$778,478
U01 · FY2021 · AI · contact PI
Pathophysiology of Human Blood Cells$576,820
T32 · FY2021 · HL · contact PI
Hematopoietic stem cell gene therapy for infantile neuronal ceroid lipofuscinosis$358,913
R01 · FY2021 · HD · contact PI
ConProject-001$237,583
U01 · FY2021 · AI · contact PI
Gene therapy targeting BCL11A to induce fetal hemoglobin and reduce sickle hemoglobin in patients with Sickle Cell Disease$196,753
R01 · FY2021 · HL · contact PI
ConProject-002$181,590
U01 · FY2021 · AI · contact PI
ConProject-006$101,851
U01 · FY2021 · AI · contact PI
ConProject-003$92,036
U01 · FY2021 · AI · contact PI
ConProject-005$74,207
U01 · FY2021 · AI · contact PI
ConProject-004$73,976
U01 · FY2021 · AI · contact PI
Disseminating Curative Biological Therapies for Rare Pediatric Diseases$1,371,788
U01 · FY2020 · TR · contact PI
Gene therapy targeting BCL11A to induce fetal hemoglobin and reduce sickle hemoglobin in patients with Sickle Cell Disease$1,200,379
OT2 · FY2020 · HL · contact PI
Gene therapy for SCID-X1 with low dose busulfan and a SIN-lentiviral vector$982,311
U01 · FY2020 · AI · contact PI
Gene therapy targeting BCL11A to induce fetal hemoglobin and reduce sickle hemoglobin in patients with Sickle Cell Disease$948,587
R01 · FY2020 · HL · contact PI
Pathophysiology of Human Blood Cells$909,057
T32 · FY2020 · HL · contact PI
Development of novel selective Rac inhibitors for refractory leukemias$585,986
R01 · FY2020 · CA · contact PI
Gene therapy targeting BCL11A to induce fetal hemoglobin and reduce sickle hemoglobin in patients with Sickle Cell Disease$1,582,593
R01 · FY2019 · HL · contact PI
Disseminating Curative Biological Therapies for Rare Pediatric Diseases$1,357,953
U01 · FY2019 · TR · contact PI
Development of novel selective Rac inhibitors for refractory leukemias$589,782
R01 · FY2019 · CA · contact PI
Pathophysiology of Human Blood Cells$541,005
T32 · FY2019 · HL · contact PI
Feasibility study randomizing IST vs URD BMT for children with aplastic anemia$258,981
R34 · FY2019 · HL · contact PI
Boston Consortium to Cure SCD - Williams/Ellen Grant$88,401
OT2 · FY2019 · HL · contact PI
Boston Consortium to Cure SCD - Williams/John Higgins$84,000
OT2 · FY2019 · HL · contact PI
Gene therapy targeting BCL11A to induce fetal hemoglobin and reduce sickle hemoglobin in patients with Sickle Cell Disease$1,582,593
R01 · FY2018 · HL · contact PI
Disseminating Curative Biological Therapies for Rare Pediatric Diseases$1,340,745
U01 · FY2018 · TR · contact PI
Pathophysiology of Human Blood Cells$860,934
T32 · FY2018 · HL · contact PI
Development of novel selective Rac inhibitors for refractory leukemias$560,804
R01 · FY2018 · CA · contact PI
Feasibility study randomizing IST vs URD BMT for children with aplastic anemia$259,035
R34 · FY2018 · HL · contact PI
Gene therapy targeting BCL11A to induce fetal hemoglobin and reduce sickle hemoglobin in patients with Sickle Cell Disease$1,673,390
R01 · FY2017 · HL · contact PI
Translational Studies of Inherited Marrow Failure and Myelodysplastic Syndromes$1,636,056
R24 · FY2017 · DK
Disseminating Curative Biological Therapies for Rare Pediatric Diseases$1,408,459
U01 · FY2017 · TR · contact PI
Pathophysiology of Human Blood Cells$640,241
T32 · FY2017 · HL · contact PI
Development of novel selective Rac inhibitors for refractory leukemias$603,034
R01 · FY2017 · CA · contact PI
Employing novel humanized murine strains to develop hematopoietic stem cell gene therapeutic approaches for very early-onset inflammatory bowel disease due to IL10-receptor deficiency.$407,902
R56 · FY2017 · AI
Feasibility study randomizing IST vs URD BMT for children with aplastic anemia$278,389
R34 · FY2017 · HL · contact PI
Pathophysiology of Human Blood Cells$3,456
T32 · FY2017 · HL · contact PI
Translational Studies of Inherited Marrow Failure and Myelodysplastic Syndromes$1,636,073
R24 · FY2016 · DK
Disseminating Curative Biological Therapies for Rare Pediatric Diseases$1,242,732
U01 · FY2016 · TR · contact PI
Development of novel selective Rac inhibitors for refractory leukemias$638,223
R01 · FY2016 · CA · contact PI
Pathophysiology of Human Blood Cells$629,782
T32 · FY2016 · HL · contact PI
Rac proteins in hematopoietic cell survival and function$410,128
R01 · FY2016 · DK · contact PI
Translational Studies of Inherited Marrow Failure and Myelodysplastic Syndromes$1,635,660
R24 · FY2015 · DK
Translational and clinical studies targeting y-globin modulation$1,461,194
U01 · FY2015 · HL · contact PI
Pathophysiology of Human Blood Cells$782,444
T32 · FY2015 · HL · contact PI
Rac proteins in hematopoietic cell survival and function$409,549
R01 · FY2015 · DK · contact PI
Translational Studies of Inherited Marrow Failure and Myelodysplastic Syndromes$1,635,392
R24 · FY2014 · DK
Translational and clinical studies targeting y-globin modulation$1,453,776
U01 · FY2014 · HL · contact PI
Gene Therapy for SCID-X1 using a self-inactivating (SIN) gammaretroviral vector$608,111
U01 · FY2014 · AI · contact PI
Pathophysiology of Human Blood Cells$538,265
T32 · FY2014 · HL · contact PI
Rac proteins in hematopoietic cell survival and function$407,232
R01 · FY2014 · DK · contact PI
RhoH GTPase in Hematopoiesis and Cancer$315,782
R01 · FY2014 · CA · contact PI
Translational Studies of Inherited Marrow Failure and Myelodysplastic Syndromes$1,692,348
R24 · FY2013 · DK
Translational and clinical studies targeting y-globin modulation$1,501,945
U01 · FY2013 · HL · contact PI
Pathophysiology of Human Blood Cells$761,996
T32 · FY2013 · HL · contact PI
Gene Therapy for SCID-X1 using a self-inactivating (SIN) gammaretroviral vector$571,624
U01 · FY2013 · AI · contact PI
Rac proteins in hematopoietic cell survival and function$405,494
R01 · FY2013 · DK · contact PI
RhoH GTPase in Hematopoiesis and Cancer$306,016
R01 · FY2013 · CA · contact PI
Gene Therapy for SCID-X1 using a self-inactivating (SIN) gammaretroviral vector$977,629
U01 · FY2012 · AI · contact PI
Pathophysiology of Human Blood Cells$777,081
T32 · FY2012 · HL · contact PI
Molecular Genetic Investigation of Pediatric Myelodysplastic Syndrome$539,247
R24 · FY2012 · DK · contact PI
RhoH GTPase in Hematopoiesis and Cancer$325,549
R01 · FY2012 · CA · contact PI
Gene Therapy for SCID-X1 using a self-inactivating (SIN) gammaretroviral vector$1,044,958
U01 · FY2011 · AI · contact PI
Pathophysiology of Human Blood Cells$684,162
T32 · FY2011 · HL · contact PI
Rac Protein in Hematopoietic Cell Survival and Function$405,811
R01 · FY2011 · DK · contact PI
RhoH GTPase in Hematopoiesis and Cancer$323,678
R01 · FY2011 · CA · contact PI
Novel therapies for Fanconi anemia$3,876,697
RC4 · FY2010 · DK · contact PI
Gene Therapy for SCID-X1 using a self-inactivating (SIN) gammaretroviral vector$1,352,430
U01 · FY2010 · AI · contact PI
Pathophysiology of Human Blood Cells$764,302
T32 · FY2010 · HL · contact PI
Development of a Pediatric Mylelodysplastic Syndrome Patient Registry$499,516
RC1 · FY2010 · DK · contact PI
Rac Protein in Hematopoietic Cell Survival and Function$409,910
R01 · FY2010 · DK · contact PI
Chemoresistance and Stem Cell Selection$398,382
R01 · FY2010 · DK · contact PI
RhoH GTPase in Hematopoiesis and Cancer$330,957
R01 · FY2010 · CA · contact PI
Pain and Sensory Processing in IC/PBS and Fibromyalgia$328,680
U01 · FY2010 · DK · contact PI
Development of a Pediatric Mylelodysplastic Syndrome Patient Registry$499,473
RC1 · FY2009 · DK · contact PI
Pathophysiology of Human Blood Cells$414,260
T32 · FY2009 · HL · contact PI
Rac Protein in Hematopoietic Cell Survival and Function$414,050
R01 · FY2009 · DK · contact PI
Chemoresistance and Stem Cell Selection$390,687
R01 · FY2009 · DK · contact PI
Pain and Sensory Processing in IC/PBS and Fibromyalgia$328,680
U01 · FY2009 · DK · contact PI
Novel Molecular and Cellular Therapies in Fanconi Anemia$319,575
R01 · FY2009 · HL · contact PI
RhoH GTPase in Hematopoiesis and Cancer$318,664
R01 · FY2009 · CA · contact PI
Pathophysiology of Human Blood Cells$578,309
T32 · FY2008 · HL · contact PI
Rac Protein in Hematopoietic Cell Survival and Function$414,050
R01 · FY2008 · DK · contact PI
Chemoresistance and Stem Cell Selection$379,305
R01 · FY2008 · DK · contact PI
Pain and Sensory Processing in IC/PBS and Fibromyalgia$328,680
U01 · FY2008 · DK · contact PI
Novel Molecular and Cellular Therapies in Fanconi Anemia$325,790
R01 · FY2008 · HL · contact PI
RhoH GTPase in Hematopoiesis and Cancer$316,480
R01 · FY2008 · CA · contact PI
Chemoresistance and Stem Cell Selection$333,525
R01 · FY2007 · DK · contact PI
Novel Molecular and Cellular Therapies in Fanconi Anemia$325,892
R01 · FY2007 · HL · contact PI
Rac Protein in Hematopoietic Cell Survival and Function$315,000
R01 · FY2007 · DK · contact PI
RhoH GTPase in Hematopoiesis and Cancer$279,026
R01 · FY2007 · CA · contact PI
Rac Protein in Hematopoietic Cell Survival and Function$60,000
R01 · FY2007 · DK · contact PI
SUBJECT REGISTRY: INTERDISCIPLINARY STUDIES OF CHRONIC MULTI-SYMPTOM ILLNESSES$35,926
M01 · FY2007 · RR · contact PI
DONATION OF PERIPHERAL BLOOD STEM CELLS FOR USE IN EXPERIMENTS$28,970
M01 · FY2007 · RR · contact PI
LOCUS OF PAIN CONTROL: NEURAL SUBSTRATES AND MODIFABILITY$22,369
M01 · FY2007 · RR · contact PI
Rac protein in hematopoietic cell survival and function$420,728
R01 · FY2006 · DK · contact PI
Chemoresistance and Stem Cell Selection$332,929
R01 · FY2006 · DK · contact PI
Novel Molecular and Cellular Therapies in Fanconi Anemia$327,523
R01 · FY2006 · HL · contact PI
Rac2 in hematopoietic proliferation$237,288
P01 · FY2006 · HL · contact PI
RhoH GTPase in Hematopoiesis and Cancer$236,104
R01 · FY2006 · CA · contact PI
SUBJECT REGISTRY: INTERDISCIPLINARY STUDIES OF CHRONIC MULTI-SYMPTOM ILLNESSES$74,602
M01 · FY2006 · RR · contact PI
DONATION OF PERIPHERAL BLOOD STEM CELLS FOR USE IN EXPERIMENTS$38,987
M01 · FY2006 · RR · contact PI
LOCUS OF PAIN CONTROL: NEURAL SUBSTRATES AND MODIFABILITY$25,037
M01 · FY2006 · RR · contact PI
Rac protein in hematopoietic cell survival and function$421,285
R01 · FY2005 · DK
RhoH GTPase in Hematopoiesis and Cancer$243,316
R01 · FY2005 · CA
SUBJECT REGISTRY: INTERDISCIPLINARY STUDIES OF CHRONIC MULTI-SYMPTOM ILLNESSES$77,197
M01 · FY2005 · RR
DONATION OF PERIPHERAL BLOOD STEM CELLS FOR USE IN EXPERIMENTS$24,896
M01 · FY2005 · RR
Rac protein in hematopoietic cell survival and function$411,665
R01 · FY2004 · DK
Peripheral Blood Stem Cells For Use in Experiments$12,135
M01 · FY2004 · RR
Subject Registry: Interdisciplinary Studies of Chronic Multi-Symptom Illnesses$9,149
M01 · FY2004 · RR
Rac protein in hematopoietic cell survival and function$399,612
R01 · FY2003 · DK
Rac protein in hematopoietic cell survival and function$402,311
R01 · FY2002 · DK
PILOT AND FEASIBILITY STUDIES$228,564
P30 · FY2002 · DK
MODULATION OF DNA DAMAGE IN HEMATOPOIETIC STEM AND PROGENITOR CELLS$220,099
P01 · FY2002 · CA
Rac2 in hematopoietic proliferation$217,365
P01 · FY2002 · HL
STEEL GENE PRODUCT AND STEM CELL PROLIFERATION$17,893
R01 · FY2002 · DK
Mouse Facility$0
P30 · FY2002 · CA
Mouse Facility$0
P30 · FY2002 · CA
Mouse Facility$0
P30 · FY2002 · CA
DOSE INTENSIFICATION BY GENE TRANSDUCTION IN CANCER$1,271,672
P01 · FY2001 · CA
PILOT AND FEASIBILITY STUDIES$228,564
P30 · FY2001 · DK
PILOT AND FEASIBILITY STUDIES$228,564
P30 · FY2001 · DK
MODULATION OF DNA DAMAGE IN HEMATOPOIETIC STEM AND PROGENITOR CELLS$220,099
P01 · FY2001 · CA
STEEL GENE PRODUCT AND STEM CELL PROLIFERATION$141,550
R01 · FY2001 · DK
CORE CENTERS OF EXCELLENCE IN MOLECULAR HEMATOLOGY$45,620
P30 · FY2001 · DK
STEEL GENE PRODUCT AND STEM CELL PROLIFERATION$19,911
R01 · FY2001 · DK
Mouse Facility$0
P30 · FY2001 · CA
DOSE INTENSIFICATION BY GENE TRANSDUCTION IN CANCER$1,245,485
P01 · FY2000 · CA
CORE CENTERS OF EXCELLENCE IN MOLECULAR HEMATOLOGY$915,000
P30 · FY2000 · DK
MODULATION OF DNA DAMAGE IN HEMATOPOIETIC STEM AND PROGENITOR CELLS$248,024
P01 · FY2000 · CA
STEEL GENE PRODUCT AND STEM CELL PROLIFERATION$187,488
R01 · FY2000 · DK
PILOT AND FEASIBILITY STUDIES$120,832
P30 · FY2000 · DK
Mouse Facility$0
P30 · FY2000 · CA